SCHEMBL27201600

SCHEMBL27201600

O=C(O)N1CCC=C(c2c[nH]c3ccccc23)C1

nearest known ligand 0.64

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.47
ALOX15 P16050 4/20 0.47
LMNA P02545 3/20 0.47
HTR1A P08908 2/20 0.47
HSD17B10 Q99714 2/20 0.47
POLB P06746 1/20 0.47
SLC6A4 P31645 1/20 0.47
HTR6 P50406 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
HTT P42858 2/20 0.45
DRD2 P14416 2/20 0.45
TDO2 P48775 1/20 0.45
HTR2A P28223 1/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
MAPT P10636 4/20 0.44
ALDH1A1 P00352 1/20 0.44
HTR2C P28335 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25168915 0.83 GOT1 (0.43) HTR6MAPT
SCHEMBL28329830 0.83 HTR2A (0.54) HTR2A
SCHEMBL27201485 0.82 MAPK1 (0.44) KDM4EALOX15LMNAHTR1AHSD17B10
SCHEMBL27791670 0.80 CDK2 (0.49) HTR2AHTR2C
SCHEMBL28097296 0.79 LMNA (0.64) KDM4EALOX15LMNAHTR1AHSD17B10
SCHEMBL30834251 0.79 MAPT (0.45) KDM4EALOX15LMNAMAPTALDH1A1
SCHEMBL30548037 0.78 KDM4E (0.62) KDM4EALOX15LMNAHTR1AHSD17B10
SCHEMBL31530785 0.75 HTR1A (0.66) KDM4EALOX15LMNAHTR1AHTT
SCHEMBL2783395 0.75 HTR1A (0.66) KDM4EALOX15LMNAHTR1AHTT
SCHEMBL27791722 0.73 CCNT1 (0.39) KDM4EALOX15LMNAPOLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS ACCUTAR BIOTECHNOLOGY INC. (US) 2024-04-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240132464-A1 HETEROCYCLIC COMPOUNDS AS E3 LIGASE INHIBITORS GID4, MDM2, XIAP KDM4E 1293/4885ALOX15 2812/4885LMNA 2914/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.